Madrigal Pharmaceuticals, Inc. Earnings

Madrigal Pharmaceuticals, Inc.’s revenue jumped 1353.76% since last year same period to $212.8Mn in the Q2 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 55.05% jump in its revenue since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit jumped 72.18% since last year same period to $-42.28Mn in the Q2 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 42.27% jump in its net profits since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit margin jumped 98.09% since last year same period to -19.87% in the Q2 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 62.77% jump in its net profit margins since last 3-months.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -3.36 - a 7.44% jump from last quarter’s estimates.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -3.36.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) jumped 73.24% since last year same period to -1.9 in the Q2 2025. This indicates that the Madrigal Pharmaceuticals, Inc. has generated 73.24% annual rate of jump in its earning per share (EPS) in the last 4 quarters.